Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00809848 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
A Phase 1 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 172
- Enrollment target
NCT00809848 is a Phase 1 study that has completed, run by Allergan. The registered enrollment target is 172 participants.
The verdict
NCT00809848, a Phase 1 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 172 participants
- Enrollment target
Study Summary
The study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution in comparison with AGN-210669 vehicle and bimatoprost ophthalmic solution dosed once-daily each morning, in subjects with ocular hypertension or primary open-angle glaucoma. Subjects will be followed for 2 weeks.
Interventions
- DRUG bimatoprost ophthalmic solution 0.03%
- DRUG AGN-210669 ophthalmic solution, 0.075%
- DRUG AGN-210669 ophthalmic solution, 0.05%
- DRUG AGN-210669 ophthalmic solution, 0.025%
- DRUG AGN-210669 vehicle ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2009-02 |
| Est. Completion | 2009-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00809848
The ClinicalTrials.gov registry entry for NCT00809848 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which bimatoprost ophthalmic solution 0.03% is the first listed.
NCT00809848 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00809848 about?
NCT00809848 is a clinical study titled "Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma". The study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution in comparison with AGN-210669 vehicle and bimatoprost ophthalmic solution dosed once-daily each morning, in subjects with ocular hypertension or primary open-angle glaucoma. Subjects will be followed for 2 weeks.
What is the current status of trial NCT00809848?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 172 participants. The study started on 2009-02. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00809848?
The interventions under investigation include: bimatoprost ophthalmic solution 0.03% (DRUG), AGN-210669 ophthalmic solution, 0.075% (DRUG), AGN-210669 ophthalmic solution, 0.05% (DRUG), AGN-210669 ophthalmic solution, 0.025% (DRUG), AGN-210669 vehicle ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT00809848?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.